A digital PCR kit for detecting multiple mutation sites of human EGFR gene
Through the digital PCR kit combined with specific primers and probe combinations, high sensitivity detection of multiple mutation sites of EGFR genes is achieved, solving the problems of low detection sensitivity and high cost in the prior art, and providing more accurate detection results and Lower sample consumption.
Patent Information
- Application Number
- CN202211548410.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-05
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-12-05
AI Technical Summary
Existing gene mutation detection methods, such as sequencing and PCR, have problems such as low sensitivity, long time, high cost and fuzzy detection results. Especially when detecting multiple mutation sites of EGFR genes, it is difficult to achieve high sensitivity and accuracy. .
Provide a digital PCR kit that combines specific primers and probe combinations to achieve four-to-five-channel high-sensitivity detection of EGFR gene 19del, T790M and L858R sites through multiple mutation detection technology, and adopts a new fluorescence quenching probe. To reduce false positives and costs, improve detection accuracy.
Achieve high sensitivity detection (sensitivity up to 0.1%) for multiple mutations of EGFR genes, reducing sample consumption, improving detection accuracy and signal-to-noise ratio, suitable for detection of scarce samples, and providing more for patients with non-small cell lung cancer. Accurate medication guidance.
Smart Images

Figure CN115820862B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a PCR kit, in particular to a digital PCR kit for detecting multiple mutation sites of human EGFR gene, belonging to the technical field of gene detection. Background Art
[0002] Epidermal growth factor receptor (EGFR) is a type I tyrosine kinase receptor and the expression product of the proto-oncogene c-erB-1 (HER-1); it participates in cell pathways such as PI3K / Akt / mTOR, RAS / RAF / MEK / ERK-MAPK, and regulates important physiological processes such as cell growth, proliferation, and transformation through these pathways; at the same time, the EGFR gene is also an important target for targeted therapy.
[0003] Studies have shown that EGFR gene mutations mainly occur in exons 19 to 21, including deletion mutations in exon 19, fragment insertions in exon 20, and point mutations in exon 21, accounting for about 90% of EGFR gene mutations. More than 80% of EGFR mutations in NSCLC patients are deletion mutations in exon 19 (Ex19De l) and L858R mutations in exon 21. Among them, exon 19 deletion mutations account for about 46%, and L858R mutations account for about 42%. The deletion of exon 19 leads to the loss of amino acid sequences in EGFR protein, thereby changing the sensitivity of cells to TKIs; the main cause of drug resistance is the TM conversion mutation at the 790th codon of exon 20 (nucleotide position 2669 base substitution); the point mutation of exon 21 is mainly the TG conversion at the 858th codon, which converts the leucine at this site into arginine, referred to as L858R. Studies have shown that the treatment of EGFR tyrosine kinase inhibitor drugs (EGFR-TKI) (such as gefitinib, erlotinib, icotinib) is closely related to EGFR gene mutations; among them, individuals with deletion mutations in exon 19# and L858R point mutations on exon 21# show strong sensitivity to such drugs, and T790M point mutations on exon 20# show resistance to such drugs. EGFR tyrosine kinase inhibitor drugs (EGFR-TKI) block signal transduction by inhibiting EGFR intracellular phosphorylation, inhibit tumor cell proliferation, and achieve targeted therapy. In addition, EGFR gene L858R and 19de l mutations cause structural changes in the EGFR intracellular tyrosine kinase functional region, which improves its ability to bind to targeted drugs. Therefore, by detecting EGFR gene L858R and 19de l mutations, as well as T790M mutations, the diagnosis and medication of the disease can be more accurate and effective.
[0004] At present, there are two commonly used methods for detecting gene mutations: sequencing and PCR. Sequencing methods include direct sequencing and next-generation sequencing (NGS). Direct sequencing is the gold standard and can detect known mutations and unknown mutations. Its disadvantages are low sensitivity, requiring an abundance of 20%, long time consumption, and high false negatives. NGS second-generation sequencing can detect multiple gene mutations at the same time, with a sensitivity of 5%, but the cost is high and the time consumption is long. Patients generally have to wait a week to get the test report.
[0005] PCR methods include high-resolution melting curve method (HRM), amplification refractory mutation system (ARMS) and digital PCR.
[0006] High-resolution melting curve is a new gene analysis technology based on the formation of melting curves of different shapes due to different melting temperatures of single nucleotides. It can detect differences in single bases, but the detection sensitivity is about 5%, and it can only detect known mutations, and is not suitable for multiplex PCR.
[0007] The amplification retardation mutation system is a new method for detecting DNA point mutations based on the PCR method. Its principle is: under strict reaction conditions, the PCR amplification reaction can only proceed normally when the 3' end of the primer is paired with the template, thereby obtaining an amplified product. When the 3' end does not match the template, the Taq DNA polymerase lacks the 3'-5' exonuclease activity, so it cannot cut off the mismatched base, resulting in the 3' end being unable to extend normally, the reaction being terminated, and no amplified product being obtained. By designing primers whose 3' end is complementary to the mutant template but not complementary to the wild-type template for PCR reaction, the presence or absence of a product of a specific length is used to determine whether there is a mutation in the sample template. The sensitivity of this method can reach 1%, and it is currently widely used for mutation detection in tumor tissues.
[0008] Digital PCR is an absolute quantitative technology for nucleic acid molecules that can directly measure the copy number of the template. The detection sensitivity can be improved by combining digital PCR with Taqman or MGB probes.
[0009] Currently, there are two common methods for detecting EGFR Ex19De l deletion mutations using digital PCR:
[0010] 1. The position of the deletion mutation in Ex19De l is relatively fixed. A detection probe or Block blocking probe is designed at the deletion position, a universal probe is designed outside the deletion position, and then a peripheral universal primer is designed to distinguish the wild type and mutant type by whether the deletion position detection probe or Block blocking probe binds. This method can only indirectly determine whether there is a sequence inconsistent with the wild type in the deletion region. When there is a SNP or other type of base change in the deletion region, this method will produce a "false positive";
[0011] 2. A dedicated deletion mutation detection probe is designed for each deletion mutation type. This method can directly and specifically detect each deletion mutation type. However, since the total concentration of probes in the detection system is too high, the fluorescence background value is too high, which leads to blurred boundaries between the "positive signal pile" and the "negative signal pile", affecting the determination of the threshold line and thus the detection. Summary of the invention
[0012] In view of this, the present invention provides a digital PCR kit for detecting multiple mutation sites of human EGFR gene, which is used for digital PCR detection of multiple mutations of human EGFR gene 19de l, T790M and L858R. The primer and probe combination provided by the present invention includes upstream primers, downstream primers, universal probes, deletion mutation detection probes dedicated to each deletion mutation type and a new quenching probe of 19de l; upstream primers, downstream primers, universal probes and mutation probes of T790M; upstream primers, downstream primers, universal probes and mutation probes of L858R; upstream primers, downstream primers and detection probes of internal reference genes; multiple mutation detections are concentrated on one chip through the method of digital PCR platform, which can accurately and conveniently realize the detection of 19de l. l. Each deletion type of T790M and L858R can be tested with four or five channels of high sensitivity, with a sensitivity of up to 0.1%. This can reduce costs, reduce sample consumption, improve detection accuracy and sensitivity, and reduce false positives, especially for ctDNA, where samples are relatively scarce. It is also convenient for the detection of other sample types such as tumor tissues, and provide certain medication guidance for patients with non-small cell lung cancer.
[0013] In order to achieve the above object, the present invention adopts the following technical solution:
[0014] A digital PCR kit for detecting multiple mutation sites of human EGFR gene, the kit comprising: 10×dPCR Buffer, dPCR enzyme, EGFR gene detection system, positive control substance, negative control substance, digital PCR chip, digital PCR oil phase A and digital PCR oil phase B;
[0015] The EGFR gene detection system includes detection primers for detecting each deletion mutation type of Ex19De l, deletion mutation detection probes and novel fluorescence quenching probes, and detection primers and Taqman fluorescence quenching probes for detecting L858R site and T790M site.
[0016] On the basis of the above technical solution, the present invention further defines:
[0017] Furthermore, the EGFR gene detection system includes 200-800nM detection primers, 50-400nM detection probes, and 50-400nM novel fluorescence quenching probes.
[0018] Further, the primers for L858R mutation detection are shown in the following sequence:
[0019] Upstream primer SEQ ID NO: 1: AGCATGTCAAGATCACAGATTT;
[0020] Upstream primer SEQ ID NO: 2: cgcagcatgtcaagatcacagat;
[0021] Upstream primer SEQ ID NO: 3: gaaaacaccgcagcatgtcaag;
[0022] Downstream primer SEQ ID NO:4: CCTCCTTCTGCATGGTATTC;
[0023] Downstream primer SEQ ID NO: 5: TTTGCCTCCTTCTGCATGGT;
[0024] Downstream primer SEQ ID NO:6: ACTTTGCCTCCTTCTGCATG;
[0025] The probe sequence is as follows:
[0026] Mutation probe SEQ ID NO: 7: 5' fluorescent label-TGGCCCGCCCAAA-3' quencher group;
[0027] Mutation probe SEQ ID NO: 8: 5' fluorescent label-TGGCCCGCCCAA-3' quencher group;
[0028] Mutation probe SEQ ID NO: 9: 5' fluorescent label-TGGGCGGGCCAAA-3' quencher group;
[0029] Mutation probe SEQ ID NO: 10: 5' fluorescent label-TGGGCGGGCCA-3' quencher group;
[0030] Universal probe SEQ ID NO: 11: 5' fluorescent label-TGGGTGCGGAAGAGAAAG-3' quencher group;
[0031] Universal probe SEQ ID NO: 12: 5' fluorescent label-TGCTGGGTGCGGAAGAG-3' quencher group;
[0032] Universal probe SEQ ID NO: 13: 5' fluorescent label-GTGCGGAAGAGAAAGAATACC-3' quencher group.
[0033] Further, the specific genotype of the Ex19de l mutation is E746-A750de l(1), and / or E746-A750de l(2), and / or L747-p753>S, and / or E746_T751>I, and / or E746_S752>V, and / or L747_T751>Q, and / or L747_E749de l, and / or L747_S752de l, and / or L747_A750>P, and / or L747_P753>Q, and / or L747_T751 de l, and / or L747_T751>P.
[0034] Further, the primer sequences for detecting the Ex19de l mutation are as follows:
[0035] Upstream primer SEQ ID NO: 14: AGTTAAAATTCCCGTCGCT;
[0036] Upstream primer SEQ ID NO: 15: TTAAAATTCCCGTCGCTAT;
[0037] Upstream primer SEQ ID NO: 16: ATCCCAGAAGGTGAGAAAGTT;
[0038] Downstream primer SEQ ID NO: 17: GCCTGAGGTTCAGAGCCAT;
[0039] Downstream primer SEQ ID NO: 18: CAAAGCAGAAACTCACATCG;
[0040] Downstream primer SEQ ID NO: 19: GAGAAAAAGGTGGGCCTGAG;
[0041] The detection probe sequences are as follows:
[0042] Mutation probe de l 1 SEQ ID NO: 20: 5' fluorescent label-TCGGAGATGTTTTGATAGCGACG-3' quencher group;
[0043] Mutation probe de l 1 SEQ ID NO: 21: 5' fluorescent label-ttcggagatgttttgatagcgac-3' quencher group;
[0044] Mutation probe de l 1 SEQ ID NO: 22: 5' fluorescent label-ctttcggagatgttttgatagcg-3' quencher group;
[0045] Mutation probe de l 2 SEQ ID NO: 23: 5' fluorescent label - CGGAGATGTCTTGATAGCGACG - 3' quencher group;
[0046] Mutation probe de l 2 SEQ ID NO: 24: 5' fluorescent label-ttcggagatgtcttgatagcgac-3' quencher group;
[0047] Mutation probe de l 2 SEQ ID NO: 25: 5' fluorescent label-gctttcggagatgtcttgatagcg-3' quencher group;
[0048] Mutation probe de l 3 SEQ ID NO: 26: 5' fluorescent label-TGGCTTTCGGAACCTTGATAGC-3' quencher group;
[0049] Mutation probe de l 3 SEQ ID NO: 27: 5' fluorescent label-gctttcggaAccttgatagcgac-3' quencher group;
[0050] Mutation probe de l 3 SEQ ID NO: 28: 5' fluorescent label-ctttcggaAccttgatagcgacgg-3' quencher group;
[0051] Mutation probe de l4 SEQ ID NO: 29: 5' fluorescent label-TGGCTTTCGATTCCTTGATAGCG-3' quencher group;
[0052] Mutation probe de l4 SEQ ID NO: 30: 5' fluorescent label-TTGGCTTTCGATTCCTTGATAGC-3' quencher group;
[0053] Mutation probe de l4 SEQ ID NO: 31: 5' fluorescent label-ggctttcgattccttgatagcgac-3' quencher group;
[0054] Mutation probe de l5 SEQ ID NO: 32: 5' fluorescent label-TGGCTTTCGGAGATTCCTTGATAG-3' quencher group;
[0055] Mutation probe de l5 SEQ ID NO: 33: 5' fluorescent label-ctttcggagattccttgatagcga-3' quencher group;
[0056] Mutation probe de l5 SEQ ID NO: 34: 5' fluorescent label-CGGAGATTCCTTGATAGCGACG-3' quencher group;
[0057] Universal probe SEQ ID NO: 35: 5' fluorescent label-AGCCAACAAGGAA-3' quencher group;
[0058] Universal probe SEQ ID NO: 36: 5' fluorescent label-CGAAAGCCAACAAGGAAATCCTCG-3' quencher group;
[0059] Universal probe SEQ ID NO: 37: 5' fluorescent label-AGCCAACAAGGAAATCCTCG-3' quencher group;
[0060] Novel fluorescence quenching probe SEQ ID NO: 38: GCTATCAA;
[0061] Novel fluorescence quenching probe SEQ ID NO:39: ACATCTCCG;
[0062] Novel fluorescence quenching probe SEQ ID NO:40: CGAAAGCCA.
[0063] Further, the primer sequences for T790M mutation detection are as follows:
[0064] Upstream primer SEQ ID NO:41: TCTGCCTCACCTCCAC;
[0065] Upstream primer SEQ ID NO:42: ATCTGCCTCACCTCCAC;
[0066] Upstream primer SEQ ID NO:43: ATCTGCCTCACCTCCA;
[0067] Downstream primer SEQ ID NO:44: TTGTGTTCCCGGACATAG;
[0068] Downstream primer SEQ ID NO:45: TTTGTGTTCCCGGACATAG;
[0069] Downstream primer SEQ ID NO:46: TTTGTGTTCCCGGACATA;
[0070] The detection probe sequences are as follows:
[0071] Mutation probe SEQ ID NO: 47: 5' fluorescent label-CAGCTGCATGATGA-3' quencher group;
[0072] Mutation probe SEQ ID NO: 48: 5' fluorescent label-AGCTGCATGATGAT-3' quencher group;
[0073] Mutation probe SEQ ID NO: 49: 5' fluorescent label-AGCTGCATGATG-3' quencher group;
[0074] Mutation probe SEQ ID NO: 50: 5' fluorescent label-AGCTGCATGATGA-3' quencher group;
[0075] Universal probe SEQ ID NO: 51: 5' fluorescent label-AAGCTGCGTGATGA-3' quencher group;
[0076] Universal probe SEQ ID NO: 52: 5' fluorescent label-GCTGCGTGATGA-3' quencher group;
[0077] Universal probe SEQ ID NO: 53: 5' fluorescent label-AGCTGCGTGATGA-3' quencher group.
[0078] Further, any one or two of BHQ1, BHQ2, BHQ3, MGB, phosphorylation are labeled at the 5' end and / or 3' end of the sequence;
[0079] The fluorescent label is any one of FAM, HEX, VI C, ROX, CY5, and CY5.5; the 3' end is any one of BHQ1, BHQ2, BHQ3, MGB, and phosphorylation.
[0080] Furthermore, the kit includes the same fluorescent probe as the Ex19De l mutation probe, wild-type probes for L858R and T790M and / or a universal probe using another four different fluorescent channels.
[0081] Further, the PCR Buffer includes 10-100mM Tris-HCl, 1-5mM MgCl2, 0-100mM KCl, 0-50mM ammonium sulfate, 0.2-0.4mM dNTP, 0.01%-0.5% Tween-20, 0.01%-0.5% polyethylene glycol, 0.01%-0.5% Triton X-100, and 0.01%-0.5% CA-630;
[0082] The dPCR enzyme includes 1-5U Taq DNA polymerase, 0.01-1U UNG enzyme, and 20-80% glycerol.
[0083] Furthermore, the oil phase A for digital PCR includes hydrogen-containing silicone oil with a hydrogen content of 0.1%-0.8% and 0.01%-0.5% Triton X-100;
[0084] The oil phase B for digital PCR includes vinyl-terminated silicone oil, 0.1% of platinum catalyst, and 0.15% of EM90.
[0085] The present invention achieves the following technical effects:
[0086] 1. High throughput: This kit combines Ex19De l mutation, T790M mutation and L858R site into one chip for detection, which improves the detection throughput, reduces the cost of reagents and consumables, and improves the utilization rate of clinical samples;
[0087] 2. High sensitivity: Under complex detection background, the detection sensitivity of this kit can still reach 0.1%, which is more advantageous than the 1% sensitivity of the ARMS method;
[0088] 3. Strong specificity: This kit is designed with specific mutant detection probes for various Ex19De l mutants of the EGFR gene. The primer and probe combination has strong specificity in PCR amplification reaction, and there is no non-specific signal in the 20ng wild-type genome background;
[0089] 4. The positive and negative signal stacks are concentrated, the signal-to-noise ratio is high, and the fluorescence channel is saved: This kit adopts a new quenching probe method, which only occupies one fluorescence channel to directly and specifically detect 5-12 deletion mutations of Ex19De l, overcoming the high fluorescence background value caused by the high total concentration of the probe. The boundary between the "positive signal stack" and the "negative signal stack" is clear, the threshold line is accurately determined, and the detection results are reliable. BRIEF DESCRIPTION OF THE DRAWINGS
[0090] Figure 1 This is a diagram of the digital PCR test results of Example 2 of the present invention;
[0091] Figure 2This is a diagram of the digital PCR test results of Example 2 of the present invention;
[0092] Figure 3 This is a diagram of the digital PCR detection results of Example 2 of the present invention. DETAILED DESCRIPTION
[0093] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0094] Example 1
[0095] A digital PCR kit for detecting multiple mutation sites of human EGFR gene, including: 10×dPCR Buffer (10-100mMTris-HCl, 1-5mM MgCl2, 0-100mM KCl, 0-50mM ammonium sulfate, 0.2-0.4mM dNTP, 0.01%-0.5% Tween-20, 0.01%-0.5% polyethylene glycol, 0.01%-0.5% Triton X-100, 0.01%-0.5% CA-630), dPCR enzyme (1-5U Taq DNA polymerase, 0.01-1U UNG enzyme, 20-80% glycerol), EGFR gene detection system (200-800nM detection primers, 50-400nM detection probes, 50-400nM novel fluorescence quenching probes, sequences as shown in Tables 1-3 below), positive control, negative control, digital PCR chip, digital PCR oil phase A (hydrogen-containing silicone oil with a hydrogen content of 0.1%-0.8%, 0.01%-0.5% Triton X-100) and digital PCR oil phase B (terminated vinyl silicone oil, 0.1% platinum catalyst, 0.15% EM90);
[0096] Table 1 L858R mutation detection sequence
[0097]
[0098] Table 2Ex19de l mutation detection sequence
[0099]
[0100]
[0101] Table 3 T790M mutation detection sequence
[0102]
[0103]
[0104] Optionally, any one or two of BHQ1, BHQ2, BHQ3, MGB, phosphorylation are labeled at the 5' end and / or 3' end of the sequence;
[0105] The fluorescent label is any one of FAM, HEX, VI C, ROX, CY5, and CY5.5; the 3' end is any one of BHQ1, BHQ2, BHQ3, MGB, and phosphorylation;
[0106] The nucleic acid sequence may be complementary to the 5' end or the 3' end of the probe to be quenched;
[0107] The Tm value of the complementary nucleic acid sequence can be selected to be ≤50°C, or ≤60°C;
[0108] The kit includes the same fluorescent probe as the Ex19De l mutation probe, wild-type probes for L858R and T790M and / or a universal probe using an additional 4 different fluorescent channels.
[0109] Example 2
[0110] Detection of the effect of primers and probes in the kit in Example 1
[0111] 1. Preparation of primer probes for the kit of this application
[0112] The sequences in Tables 1-3 above and other components in the digital PCR kit were selected as the detection system, and a mixed system without the novel fluorescent quenching probe in Table 2 was used as a control.
[0113] 2. Preparation of amplification reagents
[0114] Prepare the amplification reagents according to Table 4 below.
[0115] Table 4 Reagent components and contents
[0116] Reagent components Addition volume (μL) 10×dPCRBuffer 3 dPCR enzymes 1 Human EGFR gene detection system 11 DNA samples 15
[0117] 3. Sample injection
[0118] According to the PCR operating instructions, the reaction solution prepared in step 2 was injected into the digital PCR chip.
[0119] 4. PCR reaction
[0120] The amplification procedure is shown in Table 5.
[0121] Table 5 Amplification procedures
[0122]
[0123] 5. Data reading
[0124] Take out the chip from the dedicated PCR instrument and put the chip into the digital PCR chip reader for reading and analysis.
[0125] 6. Results
[0126] The results are as follows Figure 1-3 As shown in the figure, Figure 1 The negative and positive dividing lines in the comparison detection reagent are not obvious; while the positive signal and negative signal dividing lines in the detection results of the kit of the present application are obvious, and the signal-to-noise ratio is high.
[0127] It is shown that the detection effect is better after adding the new quenching probe to the kit of this application.
[0128] Example 3
[0129] The minimum detection limit of the kit in Example 1
[0130] 1. Preparation of minimum detection limit quality control products
[0131] The detection limit reference samples cover each mutation type, including seven corporate reference samples (prepared by mixing mutation type plasmids with human EGFR wild-type cell line DNA), and the mutation ratios were quantified using digital PCR.
[0132] The sample with a DNA template amount of 20 ng and a mutation ratio of 0.1% was used as the detection limit quality control product of this embodiment. The minimum detection limit quality control product is specifically shown in Table 6:
[0133] Table 6 Minimum detection limit quality control products
[0134]
[0135] 2. The steps are the same as in Example 2.
[0136] 3. Mutation rate calculation and quality control of the kit
[0137] The kit of the present application can quantitatively detect Ex19De l mutant, Ex19De l wild type, T790M mutant, T790M wild type, L858R mutant and L858R wild type. The mutation rate of L858R can be calculated by L858R mutant / (L858R mutant+L858R wild type); the mutation rate of T790M can be calculated by T790M mutant / (T790M mutant+T790M wild type); the mutation rate of Ex19DEL can be calculated by 19de l mutant / (19de l mutant+19de l wild type);
[0138] L858R quantitative results (L858R mutant + L858R wild type), or T790M quantitative results (T790M mutant + T790M wild type), or 19de l mutant / (19de l mutant + 19de l wild type), or internal reference genes are used to control the concentration and quality of template DNA, which makes the system of the present invention more perfect.
[0139] 4. Repeatability test was performed 20 times, and the experimental results are shown in Table 7:
[0140] Table 7 Repeatability test results
[0141] name Qualitative results EGFRL858R Positive EGFRE746-A750del(1) Positive EGFRT790M Positive E746-A750del(2) Positive L747-p753>S Positive E746-S752>V Positive L747-T751del Positive
[0142] As shown in Table 7, when the amount of DNA template is 20 ng, the kit of the present application can detect 0.1% of EGFR mutation.
[0143] Example 4
[0144] Repeatability test of the kit in Example 1
[0145] 1. Preparation of reproducible quality control products
[0146] 2. DNA plasmids with EGFR gene L858R, T790M and 19de l mutations and EGFR-negative cell line genomic DNA were selected and mixed in proportion to prepare a sample with a mutation ratio of 1% of the mutant as a repeatability control product of this example, as shown in Table 8:
[0147] Table 8 Repeatability Control Products
[0148]
[0149]
[0150] 3. The steps are the same as in Example 2.
[0151] 4. Repeatability test was performed 10 times, and the experimental results are shown in Table 9-15:
[0152] Table 9
[0153]
[0154] From the experimental results in Table 9, it can be seen that after repeated inspections for 10 times, the positive coincidence rate of the test results is 100%;
[0155] Table 10
[0156]
[0157]
[0158] From the experimental results in Table 10, it can be seen that after repeated inspections for 10 times, the positive coincidence rate of the test results is 100%;
[0159] Table 11
[0160]
[0161] From the experimental results in Table 11, it can be seen that after repeated inspections for 10 times, the positive coincidence rate of the test results is 100%;
[0162] Table 12
[0163]
[0164]
[0165] From the experimental results in Table 12, it can be seen that after repeated inspections for 10 times, the positive coincidence rate of the test results is 100%;
[0166]
[0167] From the experimental results in Table 13, it can be seen that after repeated inspections for 10 times, the positive coincidence rate of the test results is 100%;
[0168] Table 14
[0169]
[0170]
[0171] From the experimental results in Table 14, it can be seen that after repeated inspections for 10 times, the positive coincidence rate of the test results is 100%;
[0172] Table 15
[0173]
[0174] From the experimental results in Table 15, it can be seen that after repeated inspection for 10 times, the positive coincidence rate of the test results is 100%.
Claims
1. A digital PCR kit for detecting multiple mutation sites of human EGFR gene, characterized in that: The kit comprises: 10×dPCR Buffer, dPCR enzyme, EGFR gene detection system, positive control, negative control, digital PCR chip, digital PCR oil phase A, and digital PCR oil phase B; The EGFR gene detection system includes primers, mutation probes, universal probes and novel fluorescence quenching probes for detecting Ex19Del mutations. The specific genotypes of Ex19del mutations are E746-A750del (1), E746-A750del (2), L747-p753>S, E746_S752>V and L747_T751 del. Primers, mutation probes, and universal probes for L858R mutation detection; Primers, mutation probes, and universal probes for T790M mutation detection; The primers for L858R mutation detection are shown in the following sequence: Upstream primer SEQ ID NO: 1: AGCATGTCAAGATCACAGATTT; Upstream primer SEQ ID NO: 2: cgcagcatgtcaagatcacagat; Upstream primer SEQ ID NO: 3: gaaaacaccgcagcatgtcaag; Downstream primer SEQ ID NO:4: CCTCCTTCTGCATGGTATTC; Downstream primer SEQ ID NO: 5: TTTGCCTCCTTCTGCATGGT; Downstream primer SEQ ID NO:6: ACTTTGCCTCCTTCTGCATG; The probe sequence is as follows: Mutation probe SEQ ID NO: 7: 5' fluorescent label-TGGCCCGCCCAAA-3' quencher group; Mutation probe SEQ ID NO: 8: 5' fluorescent label-TGGCCCGCCCAA-3' quencher group; Mutation probe SEQ ID NO: 9: 5' fluorescent label-TGGGCGGGCCAAA-3' quencher group; Mutation probe SEQ ID NO: 10: 5' fluorescent label-TGGGCGGGCCA-3' quencher group; Universal probe SEQ ID NO: 11: 5' fluorescent label-TGGGTGCGGAAGAGAAAG-3' quencher group; Universal probe SEQ ID NO: 12: 5' fluorescent label-TGCTGGGTGCGGAAGAG-3' quencher group; Universal probe SEQ ID NO: 13: 5' fluorescent label-GTGCGGAAGAGAAAGAATACC-3' quencher group; The primer sequences for detecting Ex19del mutation are as follows: Upstream primer SEQ ID NO: 14: AGTTAAAATTCCCGTCGCT; Upstream primer SEQ ID NO: 15: TTAAAATTCCCGTCGCTAT; Upstream primer SEQ ID NO: 16: ATCCCAGAAGGTGAGAAAGTT; Downstream primer SEQ ID NO: 17: GCCTGAGGTTCAGAGCCAT; Downstream primer SEQ ID NO: 18: CAAAGCAGAAACTCACATCG; Downstream primer SEQ ID NO: 19: GAGAAAAAGGTGGGCCTGAG; The detection probe sequences are as follows: Mutation probe del 1 SEQ ID NO: 20: 5' fluorescent label-TCGGAGATGTTTTGATAGCGACG-3' quencher group; Mutation probe del 1 SEQ ID NO: 21: 5' fluorescent label-ttcggagatgttttgatagcgac-3' quencher group; Mutation probe del 1 SEQ ID NO: 22: 5' fluorescent label-ctttcggagatgttttgatagcg-3' quencher group; Mutation probe del 2 SEQ ID NO: 23: 5' fluorescent label - CGGAGATGTCTTGATAGCGACG - 3' quencher group; Mutation probe del 2 SEQ ID NO: 24: 5' fluorescent label-ttcggagatgtcttgatagcgac-3' quencher group; Mutation probe del 2 SEQ ID NO: 25: 5' fluorescent label-gctttcggagatgtcttgatagcg-3' quencher group; Mutation probe del 3 SEQ ID NO: 26: 5' fluorescent label-TGGCTTTCGGAACCTTGATAGC-3' quencher group; Mutation probe del 3 SEQ ID NO: 27: 5' fluorescent label-gctttcggaAccttgatagcgac-3' quencher group; Mutation probe del 3 SEQ ID NO: 28: 5' fluorescent label -ctttcggaAccttgatagcgacgg-3' quencher group; Mutation probe del4 SEQ ID NO: 29: 5' fluorescent label-TGGCTTTCGATTCCTTGATAGCG-3' quencher group; Mutation probe del4 SEQ ID NO:30: 5' fluorescent label-TTGGCTTTCGATTCCTTGATAGC-3' quencher group; Mutation probe del4 SEQ ID NO:31: 5' fluorescent label-ggctttcgattccttgatagcgac-3' quencher group; Mutation probe del5 SEQ ID NO:32: 5' fluorescent label-TGGCTTTCGGAGATTCCTTGATAG-3' quencher group; Mutation probe del5 SEQ ID NO:33: 5' fluorescent label-ctttcggagattccttgatagcga-3' quencher group; Mutation probe del5 SEQ ID NO:34: 5' fluorescent label-CGGAGATTCCTTGATAGCGACG-3' quencher group; Universal probe SEQ ID NO: 35: 5' fluorescent label-AGCCAACAAGGAA-3' quencher group; Universal probe SEQ ID NO: 36: 5' fluorescent label-CGAAAGCCAACAAGGAAATCCTCG-3' quencher group; Universal probe SEQ ID NO: 37: 5' fluorescent label-AGCCAACAAGGAAATCCTCG-3' quencher group; Novel fluorescence quenching probe SEQ ID NO: 38: GCTATCAA; Novel fluorescence quenching probe SEQ ID NO:39: ACATCTCCG; Novel fluorescence quenching probe SEQ ID NO:40: CGAAAGCCA; The primer sequences for T790M mutation detection are as follows: Upstream primer SEQ ID NO:41: TCTGCCTCACCTCCAC; Upstream primer SEQ ID NO:42: ATCTGCCTCACCTCCAC; Upstream primer SEQ ID NO:43: ATCTGCCTCACCTCCA; Downstream primer SEQ ID NO:44: TTGTGTTCCCGGACATAG; Downstream primer SEQ ID NO:45: TTTGTGTTCCCGGACATAG; Downstream primer SEQ ID NO:46: TTTGTGTTCCCGGACATA; The detection probe sequences are as follows: Mutation probe SEQ ID NO: 47: 5' fluorescent label-CAGCTGCATGATGA-3' quencher group; Mutation probe SEQ ID NO: 48: 5' fluorescent label-AGCTGCATGATGAT-3' quencher group; Mutation probe SEQ ID NO: 49: 5' fluorescent label-AGCTGCATGATG-3' quencher group; Mutation probe SEQ ID NO: 50: 5' fluorescent label-AGCTGCATGATGA-3' quencher group; Universal probe SEQ ID NO: 51: 5' fluorescent label-AAGCTGCGTGATGA-3' quencher group; Universal probe SEQ ID NO: 52: 5' fluorescent label-GCTGCGTGATGA-3' quencher group; Universal probe SEQ ID NO: 53: 5' fluorescent label-AGCTGCGTGATGA-3' quencher group; The oil phase A for digital PCR includes hydrogen-containing silicone oil with a hydrogen content of 0.1%-0.8% and 0.01%-0.5% Triton X-100; The oil phase B for digital PCR includes vinyl-terminated silicone oil, 0.1% of platinum catalyst, and 0.15% of EM90.
2. The digital PCR kit for detecting multiple mutation sites of human EGFR gene according to claim 1, characterized in that: The EGFR gene detection system comprises 200-800 nM primers, 50-400 nM mutation probes and universal probes, and 50-400 nM novel fluorescence quenching probes.
3. The digital PCR kit for detecting multiple mutation sites of human EGFR gene according to claim 1, characterized in that: The fluorescent label at the 5' end of the probe is any one of FAM, HEX, VIC, ROX, CY5, and CY5.5; the quenching group at the 3' end of the probe is any one of BHQ1, BHQ2, BHQ3, and MGB.
4. The digital PCR kit for detecting multiple mutation sites of human EGFR gene according to claim 1, characterized in that: The PCR Buffer includes 10-100 mM Tris-HCl, 1-5 mM MgCl2, 0-100 mM KCl, 0-50 mM ammonium sulfate, 0.2-0.4 mM dNTP, 0.01%-0.5% Tween-20, 0.01%-0.5% polyethylene glycol, 0.01%-0.5% Triton X-100, and 0.01%-0.5% CA-630; The dPCR enzyme includes 1-5U Taq DNA polymerase, 0.01-1U UNG enzyme, and 20-80% glycerol.
